CK Life Sciences signs agreement to distribute Biolidics' serology test for virus

CK Life Sciences (0775) announced that it has signed a distribution agreement with Biolidics Limited of Singapore to distribute a serology-based 10-minute rapid detection kit for Covid-19.

The signing of the Biolidics agreement enables CK Life Sciences to offer two types of testing methodologies for Covid-19 in Hong Kong. That includes a reverse transcription-polymerase chain reaction (“RT-PCR”) diagnostic kit, which is commonly used by hospitals and medical testing laboratories to confirm the diagnosis of Covid-19, as well as a serology-based rapid detection kit that can help to screen large groups of people for antibodies against SARS-CoV-2 (the virus that causes Covid-19) within a short period of time.

Biolidics’ easy-to-use Rapid Detection Kit detects IgM/IgG antibodies against SARS-CoV-2 in 10 minutes, using serum, plasma or whole blood samples, with an accuracy of more than 95 percent when validated against clinical diagnosis of Covid-19.

The Rapid Detection Kit has received provisional authorization from Singapore’s Health Sciences Authority as well as approval from the Food and Drug Administration of the Philippines. It has also obtained CE Marking, enabling commercialization in the European Union. In addition, it is completing a listing process with the US FDA, for distribution, marketing, and sales to healthcare institutions.